September 1, 2021

On Outset Medical

 The Fool owns shares of Outset Medical, a company that just went public last year.  They combine several kidney dialysis machines into one, which saves a tremendous amount of money.  The device is FDA approved.  The company is not profitable yet. 

August 27, 2021

On Elastic

 As noted here, Elastic is a search company, but they power some of the world's top websites.  

"Elastic powers Uber's ride-hailing app, helping the company pair drivers with riders in close proximity. And Elastic powers the search engine behind Shopify's help documentation, enabling merchants to quickly find the appropriate information."

"According to DB Engines, Elastic is the most popular enterprise search engine on the market, outranking second-place Splunk by a wide margin."

The company just reported EPS of .04 as opposed to an expected .11 EPS loss.  The Fools owns shares.   

August 23, 2021

On Farfetch

 From Yahoo Finance.  The Fool owns shares. 

Insider Buying at Bryant Riley

 From InsiderArbitrage:

 

Shares of B. Riley Financial were acquired by 3 insiders:

  • Chairman and Co-CEO Bryant R. Riley acquired 150,000 shares, paying $60.90 per share for a total amount of $9.14 million. Mr. Riley increased his stake by 2.97% to 5,198,633 shares with this purchase.
  • Director Randall E. Paulson acquired 10,000 shares, paying $60.82 per share for a total amount of $608,220. Mr. Paulson increased his stake by 11.18% to 99,417 shares with this purchase.
  • CEO B. Riley Securities, Inc. Andrew Moore acquired 5,000 shares, paying $63.70 per share for a total amount of $318,500. Mr. Moore increased his stake by 2.22% to 229,758 shares with this purchase.

B. Riley is a financial services firm that kept showing up on my radar multiple times over the years either because it was acquiring public companies, was buying back its own stock or because multiple insiders were buying the stock. I started digging into the company and its myriad lines of businesses and the more I looked into it, the more I liked what I saw.

The company was founded in 1997 as a boutique research firm focused on small-cap stocks. The company went public in 2014 by merging with the publicly traded financial advisory firm Great American Group. The stock has appreciated 232% since that merger was consummated on June 18, 2014. This compares with a gain of 32% in the Russell 2000 index over the same period.

The company provides investment banking services, wealth management services (over $10 billion in assets under management), appraisals, specialty financial advisory services and retail liquidation services in addition to owning certain companies outright.

Their advisory services businesses combined with their recent penchant to acquire brands or companies outright makes me think of B. Riley as a baby Berkshire Hathaway. The siren call of discovering the next Berkshire Hathaway or the next Warren Buffett has lead many investors astray and the investment landscape is littered with the ghosts of Eddie Lampert, Sardar Biglari, Prem Watsa, etc. That said, the more I looked into B. Riley, the more intrigued I was by the company. While the stock has appreciated handsomely from its March lows, the enterprise value of the company is just $752.27 million (market cap of $684.17 million, plus $55.6 million of preferred shares and $12.5 million of net debt) and I expect years of growth from the company as it navigates a potentially challenging macroeconomic landscape

 

August 20, 2021

Boston Omaha: The One Small Cap I Can't Get Enought Of

 One Fool just loves Boston Omaha.  They are small now, but are building a large conglomerate from the ground up. 

August 9, 2021

More Insider Buying at Vertex Pharma

 Bruce I. Sachs, the lead independent director of the company’s Board since 1998 purchased 15,000 shares for $3,260,465 at an average price of $217.36.

Vertex Pharmaceuticals perked up a little after reporting Q2 revenue increased 18% year-over-year to $1.8 billion on account of sales of its cystic fibrosis
drug KAFTRIO in Europe and the continued strong performance of TRIKAFTA in the U.S. The company also raised its full-year 2021 guidance to $7.2 to $7.4 billion from its previous guidance of $6.7 to $6.9 billion in revenue. The key question for Vertex is the strength of its pipeline outside its cystic fibrosis franchise. The company currently has four drugs in phase 2 development for kidney disease, pain, sickle cell disease and beta thalassemia.

 

July 12, 2021

Undervalued and Insider Buying at Riley Financial

 The Fool has noted that Riley Financial CEO has been buying shares over the past year.  Many metrics also show that this company is still undervalued despite its recent run up. 

July 6, 2021

Small Article on Schrodinger

 The Fool has a small article on Schrodinger and why it is one of their highest conviction picks.  The author also notes that OptimizeRX is another one of his high conviction picks. 

July 4, 2021

On Avinger

 

This medical devices company could be a takeover candidate. Avinger Inc. (NASDAQ: AVGR) designs, manufactures and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. Its lumivascular platform integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

The company’s lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.

In addition, its first-generation chronic total occlusion-crossing catheters, Wildcat and Kittycat 2, employ a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across such an occlusion.

B. Riley Securities has started coverage with a $2.50 price target, which is right in line with the consensus target.

June 22, 2021

More on Chewy

 The Fool makes a good case for investing in Chewy